Two human papillomavirus (HPV) L1 viruslike particle (VLP) vaccines have been developed against HPV types 16 and 18—the 2 HPV types that account for about 70% of cervical cancers worldwide.1 Both vaccines have been found to have high prophylactic efficacy in large clinical trials.2- 6
In this issue of JAMA, Hildesheim and colleagues7 report the effect of vaccination with one of these vaccines, the bivalent HPV-16/18 vaccine, on viral clearance. These results are from an ongoing community-based trial of more than 7000 18- to 25-year-old women in Costa Rica. The main analysis of the ongoing trial, as for other recently published trials of HPV vaccines,2- 5 will focus on vaccine efficacy among women not infected with the specific HPV vaccine types at the time of enrollment. In contrast, the analysis by Hildesheim et al addresses the question of whether the vaccine can clear HPV type 16/18 infection present at the time of vaccination. The results demonstrate no effect of the vaccine on viral clearance. Among women who had HPV-16 or HPV-18 infection at enrollment, defined as HPV DNA detected in a cervical specimen, vaccine efficacy for preventing persistent infection with HPV-16, HPV-18, or both at 6 months was 2.5% (95% confidence interval [CI], −9.8% to 13.5%) and at 12 months was −2.0% (95% CI, −24.3% to 16.3%).
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 10
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.